Journal «Angiology and Vascular Surgery» • 

2001 • VOLUME 7 • №3

PHARMACOECONOMICS OF VASAPROSTAN IN CRITICAL ISCHEMIA OF THE LOWER LIMBS

V.B. Gerasimov, M.V. Avksentyeva, P.A. Vorobyov, Z.S. Barkagan, Ye.V. Derkach, V.P. Fisenko
I.M. Sechenov Moscow Medical Academy,
Interregional Society of Pharmacoeconomic Studies,
Moscow, Russia

A pharmacoeconomic analysis is made of the "typical practice" of management of patients with critical ischemia of the lower limbs (stages III-IV according to Fontaine) and of the results of the use of vasaprostan. The cost/effectiveness coefficient is computed, according to which the percentage of the "limbs saved from amputation" is taken as a criterion of the efficacy. It is demonstrated that the use of vasaprostanreduces the amputation rate 3.5-fold, makes it possible to increase the number of reconstructive operations by 30%. The cost of the treatment using vasaprostan rises only by 12-15% (from 37231 in "typical practice" to 41973 or 43530 roubles with vasaprostan use as dependent on the patient group examined. The expenses per "one saved leg" drop from 64191 roubles in typical practice – to 46124 or 49466 roubles with the use of vasaprostan.

KEY WORDS: pharmacoeconomics, vasaprostan, critical ischemia of lower.

P. 22-28

« Back

Angiologia.ru - portal for professionals
VLAANT
Lancet
HI-TECHNOLOGY MEDICINE